Advertisement

Advertisement

2022 ASCO Annual Meeting

CNS Cancers

Dabrafenib Plus Trametinib Improve Overall Response Rates vs Standard-of-Care Chemotherapy in Pediatric Patients With Low-Grade Gliomas

The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemothera...

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial...

gynecologic cancers

Benoit You, MD, PhD, on Ovarian Cancer: Who Benefits From Bevacizumab in the First-Line Setting

Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier d...

breast cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for ...

supportive care
symptom management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-l...

bladder cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in ...

multiple myeloma

Paul G. Richardson, MD, on Multiple Myeloma: New Data on Lenalidomide, Bortezomib, and Dexamethasone, With or Without ASCT

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide,...

Brentuximab Vedotin Plus Chemotherapy vs Chemotherapy Alone for Pediatric Patients With Hodgkin Lymphoma

A new study has shown that a combination of brentuximab vedotin and standard chemotherapy is safe and appears to be more effective than standard chemotherapy in pediatric patients up to age 21 with ne...

Racial/Ethnic Disparities and Cardiovascular Mortality Among Cancer Survivors

A recent large national study showed the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types. The findings are being presented by ...

Breast Cancer

Study Offers Guidance for Future Trials of Adjuvant Therapy for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer

To fully evaluate hormone-blocking therapy following surgery for patients with early-stage high-risk hormone receptor–positive/HER2-negative breast cancer, researchers should continue to track patient...

Multiple Myeloma

Including ASCT as Part of Initial Therapy Improves Progression-Free Survival in Newly Diagnosed Patients With Multiple Myeloma

The use of autologous stem cell transplantation (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed patients w...

Sarcoma

Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas

Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according ...

Breast Cancer

Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer

The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall surviv...

Colorectal Cancer

Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer

The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who re...

myelodysplastic syndromes

Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol

Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients w...

pancreatic cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates wit...

Breast Cancer

Endocrine Sensitivity Test Predicts Survival Benefit of Dose-Dense Chemotherapy for Patients With Hormone Receptor–Positive Breast Cancer

A new genomic test designed to measure the endocrine sensitivity of estrogen receptor–positive breast cancer has the potential to identify patients diagnosed with the disease who could benefit more fr...

Colorectal Cancer
Issues in Oncology

Study Reveals Racial Disparities in Guideline-Concordant Care for Patients With Early-Onset Colorectal Cancer

In a large national study, Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their White counterparts. Differences in health insurance coverage type,...

COVID-19

New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States

According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared...

Lung Cancer

Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows

Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed act...

Global Cancer Care

ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities

In a collaboration announced today, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related tar...

Colorectal Cancer

ctDNA May Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer

In patients with stage II colon cancer where cancer DNA was not present in the blood (as circulating tumor DNA, or ctDNA), adjuvant chemotherapy could be skipped without compromising recurrence-free s...

Breast Cancer

Sacituzumab Govitecan-hziy Improves Progression-Free Survival in Endocrine-Resistant Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer

Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many pr...

Solid Tumors
Immunotherapy

Nemvaleukin Alfa Alone and in Combination With Pembrolizumab for Advanced-Stage Solid Tumors

Initial results from the ARTISTRY-1 study to be presented by Vaishampayan et al at the 2022 ASCO Annual Meeting showed that an experimental drug called nemvaleukin alfa, when used alone or in combinat...

Cost of Care
Genomics/Genetics

New Study Assesses Oncologists’ Ratings of the Importance of Health Insurance and Costs for Genomic Testing

A new study led by researchers at the American Cancer Society showed physician, practice, and patient characteristics were associated with oncologists’ ratings of the importance of patient health insu...

Pancreatic Cancer
Immunotherapy

Nimotuzumab May Improve Overall Survival in Patients With KRAS Wild-Type Advanced Pancreatic Cancer

The addition of nimotuzumab, an EGFR-targeting monoclonal antibody, to gemcitabine increased overall survival in patients with KRAS wild-type advanced pancreatic cancer, particularly those who did not...

Lymphoma

Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma

Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation ...

Issues in Oncology
Solid Tumors

Race/Ethnicity and Poverty Are Associated With Worse Outcomes Among Children With High-Risk Neuroblastoma

Prior studies by the Children’s Oncology Group (COG) have demonstrated population-based disparities in late relapse rates among Black children with high-risk neuroblastoma, and trial-based disparities...

Health-Care Policy

Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer

According to a recent report by The Commmonwealth Fund, “large racial and ethnic health inequities, driven by factors both inside and outside the health-care delivery system [in the United States], ar...

Breast Cancer

Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials

A survey of patients with metastatic breast cancer found that 83% of Black respondents were somewhat or very likely to consider clinical trial participation; however, 40% of those respondents reported...

COVID-19

Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic but Varied by Race, Socioeconomic Status, and Other Factors

With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine in...

Advertisement

Advertisement



Advertisement